 Shikha Sundaram
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 24 | 2023 | 847 | 5.030 |
Why?
| | Biliary Atresia | 9 | 2024 | 224 | 3.010 |
Why?
| | Sarcopenia | 4 | 2023 | 72 | 2.510 |
Why?
| | Non-alcoholic Fatty Liver Disease | 8 | 2024 | 280 | 2.000 |
Why?
| | End Stage Liver Disease | 2 | 2021 | 73 | 1.260 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2018 | 231 | 0.860 |
Why?
| | Hepatoblastoma | 1 | 2022 | 27 | 0.820 |
Why?
| | Hypoxia | 3 | 2018 | 963 | 0.810 |
Why?
| | Hepatopulmonary Syndrome | 2 | 2021 | 26 | 0.780 |
Why?
| | Malnutrition | 1 | 2021 | 66 | 0.780 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2022 | 227 | 0.760 |
Why?
| | Child | 32 | 2024 | 19129 | 0.750 |
Why?
| | Fatty Liver | 3 | 2013 | 253 | 0.710 |
Why?
| | Liver Neoplasms | 2 | 2022 | 527 | 0.640 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 57 | 0.620 |
Why?
| | Hypertension, Portal | 1 | 2017 | 67 | 0.560 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2674 | 0.550 |
Why?
| | Waiting Lists | 4 | 2021 | 228 | 0.500 |
Why?
| | Preoperative Care | 1 | 2017 | 332 | 0.500 |
Why?
| | Liver | 7 | 2022 | 1816 | 0.480 |
Why?
| | Oxidative Stress | 2 | 2018 | 1178 | 0.460 |
Why?
| | Graft Survival | 6 | 2022 | 504 | 0.460 |
Why?
| | Cholestasis | 3 | 2023 | 228 | 0.440 |
Why?
| | Obesity | 3 | 2013 | 2746 | 0.410 |
Why?
| | Infant | 11 | 2022 | 8293 | 0.400 |
Why?
| | Liver Failure, Acute | 1 | 2011 | 63 | 0.390 |
Why?
| | Humans | 40 | 2024 | 118972 | 0.380 |
Why?
| | Metabolic Syndrome | 2 | 2013 | 394 | 0.350 |
Why?
| | Postoperative Complications | 3 | 2021 | 2235 | 0.340 |
Why?
| | Quality of Life | 3 | 2023 | 2366 | 0.330 |
Why?
| | Adolescent | 13 | 2022 | 18480 | 0.330 |
Why?
| | Metabolism, Inborn Errors | 1 | 2008 | 38 | 0.320 |
Why?
| | Infant Mortality | 1 | 2008 | 94 | 0.320 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 17 | 0.310 |
Why?
| | Portoenterostomy, Hepatic | 3 | 2022 | 64 | 0.300 |
Why?
| | Bile Acids and Salts | 1 | 2008 | 179 | 0.300 |
Why?
| | Fructose | 2 | 2022 | 204 | 0.290 |
Why?
| | Living Donors | 4 | 2022 | 319 | 0.290 |
Why?
| | Retrospective Studies | 13 | 2022 | 12978 | 0.280 |
Why?
| | Alagille Syndrome | 2 | 2024 | 37 | 0.270 |
Why?
| | Liver Diseases | 1 | 2008 | 282 | 0.270 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2023 | 43 | 0.270 |
Why?
| | Child, Preschool | 11 | 2023 | 9491 | 0.250 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2024 | 35 | 0.240 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 60 | 0.230 |
Why?
| | Health Services Accessibility | 2 | 2021 | 781 | 0.230 |
Why?
| | Biomarkers | 4 | 2024 | 3588 | 0.220 |
Why?
| | Survival Rate | 4 | 2017 | 1720 | 0.210 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 44 | 0.210 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 681 | 0.210 |
Why?
| | Airway Extubation | 1 | 2022 | 45 | 0.210 |
Why?
| | Vaccination | 2 | 2020 | 1222 | 0.210 |
Why?
| | Hepatic Veins | 1 | 2021 | 31 | 0.200 |
Why?
| | Dietary Carbohydrates | 1 | 2022 | 153 | 0.200 |
Why?
| | Abdominal Fat | 1 | 2021 | 48 | 0.200 |
Why?
| | Treatment Outcome | 7 | 2022 | 9342 | 0.200 |
Why?
| | Vascular Malformations | 1 | 2021 | 47 | 0.200 |
Why?
| | Nutritional Status | 2 | 2021 | 300 | 0.190 |
Why?
| | Portal Vein | 1 | 2021 | 90 | 0.190 |
Why?
| | Metabolic Diseases | 1 | 2021 | 103 | 0.190 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 32 | 0.190 |
Why?
| | Female | 16 | 2023 | 61564 | 0.180 |
Why?
| | Vaccines, Attenuated | 1 | 2020 | 114 | 0.180 |
Why?
| | Enteral Nutrition | 1 | 2021 | 170 | 0.180 |
Why?
| | gamma-Glutamyltransferase | 2 | 2011 | 43 | 0.180 |
Why?
| | Remission Induction | 1 | 2020 | 247 | 0.180 |
Why?
| | Eating | 1 | 2022 | 369 | 0.180 |
Why?
| | Male | 17 | 2021 | 57801 | 0.180 |
Why?
| | Postoperative Care | 1 | 2020 | 237 | 0.170 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 240 | 0.170 |
Why?
| | Transplant Recipients | 1 | 2020 | 148 | 0.170 |
Why?
| | Cohort Studies | 4 | 2018 | 5116 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1200 | 0.160 |
Why?
| | Body Mass Index | 2 | 2018 | 2092 | 0.160 |
Why?
| | Thioguanine | 1 | 2017 | 20 | 0.150 |
Why?
| | Azathioprine | 1 | 2017 | 51 | 0.150 |
Why?
| | Aspartate Aminotransferases | 2 | 2022 | 95 | 0.150 |
Why?
| | Hepatitis, Autoimmune | 1 | 2017 | 33 | 0.150 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.150 |
Why?
| | Anesthetics, Intravenous | 1 | 2017 | 34 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2021 | 5255 | 0.150 |
Why?
| | Glucose | 1 | 2022 | 953 | 0.150 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 248 | 0.150 |
Why?
| | Pediatrics | 2 | 2016 | 985 | 0.150 |
Why?
| | Propofol | 1 | 2017 | 49 | 0.150 |
Why?
| | Adiposity | 1 | 2021 | 516 | 0.140 |
Why?
| | Societies, Medical | 1 | 2020 | 703 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 900 | 0.140 |
Why?
| | Family Relations | 1 | 2017 | 85 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2021 | 496 | 0.140 |
Why?
| | Endoscopy, Digestive System | 1 | 2017 | 111 | 0.140 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 99 | 0.130 |
Why?
| | Aldehydes | 1 | 2016 | 154 | 0.130 |
Why?
| | Nicardipine | 1 | 2015 | 6 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2017 | 132 | 0.130 |
Why?
| | Insulin Resistance | 2 | 2021 | 1180 | 0.130 |
Why?
| | Pediatric Obesity | 1 | 2021 | 524 | 0.130 |
Why?
| | Gastroenterology | 1 | 2016 | 158 | 0.120 |
Why?
| | Tacrolimus | 1 | 2015 | 151 | 0.120 |
Why?
| | Immunization | 1 | 2016 | 412 | 0.120 |
Why?
| | Health Policy | 1 | 2017 | 333 | 0.120 |
Why?
| | Registries | 3 | 2022 | 1810 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4596 | 0.120 |
Why?
| | Pilot Projects | 1 | 2018 | 1419 | 0.120 |
Why?
| | Dietary Sucrose | 1 | 2013 | 55 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1474 | 0.110 |
Why?
| | Sweetening Agents | 1 | 2013 | 52 | 0.110 |
Why?
| | Eosinophilic Esophagitis | 1 | 2017 | 308 | 0.110 |
Why?
| | Food Hypersensitivity | 1 | 2017 | 260 | 0.110 |
Why?
| | Chronic Disease | 1 | 2018 | 1636 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2012 | 324 | 0.100 |
Why?
| | Steroids | 1 | 2012 | 153 | 0.100 |
Why?
| | Hyperuricemia | 1 | 2013 | 134 | 0.100 |
Why?
| | Hemochromatosis | 1 | 2011 | 9 | 0.100 |
Why?
| | Hyperbilirubinemia | 1 | 2011 | 16 | 0.100 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 22 | 0.100 |
Why?
| | Inflammation | 1 | 2022 | 2566 | 0.100 |
Why?
| | International Normalized Ratio | 1 | 2011 | 45 | 0.100 |
Why?
| | Nutrition Surveys | 1 | 2012 | 233 | 0.100 |
Why?
| | Reoperation | 2 | 2015 | 557 | 0.100 |
Why?
| | Length of Stay | 2 | 2022 | 1032 | 0.100 |
Why?
| | Parenteral Nutrition | 1 | 2012 | 92 | 0.100 |
Why?
| | Alanine Transaminase | 1 | 2011 | 152 | 0.090 |
Why?
| | Regression Analysis | 1 | 2013 | 983 | 0.090 |
Why?
| | Herpes Simplex | 1 | 2011 | 90 | 0.090 |
Why?
| | Prevalence | 2 | 2017 | 2326 | 0.090 |
Why?
| | Uric Acid | 1 | 2013 | 354 | 0.090 |
Why?
| | Odds Ratio | 1 | 2012 | 996 | 0.090 |
Why?
| | Models, Statistical | 1 | 2013 | 636 | 0.090 |
Why?
| | Overweight | 1 | 2012 | 502 | 0.080 |
Why?
| | Pruritus | 1 | 2008 | 60 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4552 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2012 | 467 | 0.080 |
Why?
| | Hospitalization | 1 | 2017 | 1785 | 0.080 |
Why?
| | Antibiotic Prophylaxis | 1 | 2008 | 100 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 1901 | 0.080 |
Why?
| | United States | 5 | 2021 | 12555 | 0.070 |
Why?
| | Energy Intake | 2 | 2023 | 447 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6412 | 0.070 |
Why?
| | Prospective Studies | 2 | 2021 | 6471 | 0.070 |
Why?
| | Comorbidity | 1 | 2009 | 1527 | 0.060 |
Why?
| | Aged | 1 | 2022 | 19657 | 0.060 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 79 | 0.060 |
Why?
| | Risk Factors | 2 | 2017 | 9000 | 0.060 |
Why?
| | Sugars | 1 | 2023 | 32 | 0.060 |
Why?
| | Graft Rejection | 2 | 2017 | 555 | 0.050 |
Why?
| | Vaccines | 2 | 2017 | 380 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3443 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2022 | 203 | 0.050 |
Why?
| | Age Factors | 1 | 2008 | 2995 | 0.050 |
Why?
| | North America | 1 | 2022 | 266 | 0.050 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2023 | 157 | 0.050 |
Why?
| | Risk Assessment | 2 | 2022 | 3057 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 245 | 0.050 |
Why?
| | Incidence | 2 | 2017 | 2424 | 0.050 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 176 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2174 | 0.040 |
Why?
| | Fatigue | 1 | 2021 | 297 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2022 | 545 | 0.040 |
Why?
| | Young Adult | 1 | 2013 | 10793 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2017 | 23 | 0.040 |
Why?
| | Body Composition | 1 | 2021 | 653 | 0.040 |
Why?
| | Contraindications, Drug | 1 | 2017 | 7 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 59 | 0.040 |
Why?
| | Transplantation Immunology | 1 | 2017 | 31 | 0.040 |
Why?
| | Diet Therapy | 1 | 2017 | 38 | 0.040 |
Why?
| | Palivizumab | 1 | 2016 | 13 | 0.040 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 58 | 0.040 |
Why?
| | Liver Failure | 1 | 2016 | 85 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 403 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1153 | 0.030 |
Why?
| | Canada | 1 | 2016 | 340 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 200 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2015 | 111 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2021 | 2513 | 0.030 |
Why?
| | Immunization Programs | 1 | 2016 | 206 | 0.030 |
Why?
| | Bariatric Surgery | 1 | 2017 | 166 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 187 | 0.030 |
Why?
| | Drug Interactions | 1 | 2015 | 352 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1166 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2017 | 355 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 736 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 693 | 0.030 |
Why?
| | Skinfold Thickness | 1 | 2012 | 46 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1868 | 0.030 |
Why?
| | Animals | 2 | 2013 | 33381 | 0.030 |
Why?
| | Adult | 1 | 2013 | 31512 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 437 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 5690 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 493 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1440 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2013 | 601 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4196 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 589 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 4708 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3730 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1798 | 0.010 |
Why?
|
|
Sundaram's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|